167 related articles for article (PubMed ID: 29998007)
1. Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer.
Katanyoo K; Chitapanarux I; Tungkasamit T; Chakrabandhu S; Chongthanakorn M; Jiratrachu R; Kridakara A; Townamchai K; Muangwong P; Tovanabutra C; Chomprasert K
J Gastrointest Oncol; 2018 Jun; 9(3):425-434. PubMed ID: 29998007
[TBL] [Abstract][Full Text] [Related]
2. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
Soni A; Aspinall SL; Zhao X; Good CB; Cunningham FE; Chatta G; Passero V; Smith KJ
Oncol Res; 2014; 22(5-6):311-9. PubMed ID: 26629943
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
10. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of adjuvant chemotherapy after concurrent chemoradiation in patients with locally advanced cervical cancer.
Rongsriyam K; Tangjitgamol S; Leelahavarong P; Teerawattananon Y; Tharavichitkul E; Tovanabutra C; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara LCA; Hanprasertpong J; Khunnarong J; Chottetanaprasith T; Lorvidhaya V
J Med Imaging Radiat Oncol; 2020 Dec; 64(6):873-881. PubMed ID: 32978901
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.
Shibahara H; Shiroiwa T; Ishiguro M; Nakamura M; Hasegawa J; Yamaguchi S; Masuda Y; Sakamoto J; Tomita N; Fukuda T
Eur J Health Econ; 2022 Sep; 23(7):1159-1171. PubMed ID: 35072852
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
Front Oncol; 2022; 12():904372. PubMed ID: 36176384
[TBL] [Abstract][Full Text] [Related]
19. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?
Chan AK; Wong AO; Jenken DA
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1413-9. PubMed ID: 20338475
[TBL] [Abstract][Full Text] [Related]
20. Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan.
Takata K; Fujita KI; Kubota Y; Ishida H; Ichikawa W; Shimada K; Sekikawa T; Taki-Takemoto I; Kamei D; Iwai S; Sasaki Y
J Pharm Health Care Sci; 2016; 2():30. PubMed ID: 27843573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
